Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial Open Access

Publication
Written by Jamison Wright

https://academic.oup.com/ajrccm/advance-article/doi/10.1093/ajrccm/aamag155/8571410?login=false

Jamison Wright https://jamisonwright.com
Previous

Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Next

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine